Cala has made its kIQ Plus wrist-worn neuromodulation system nationally available for action hand tremor in essential tremor and Parkinson's disease, following FDA clearance earlier this year. The device delivers peripheral nerve stimulation with selectable waveform modes and adaptive calibration, and trial data presented at the American Academy of Neurology meeting showed greater functional improvement when patients used their preferred waveform. Between 76% and 89% of participants achieved at least a one-point reduction on clinician-rated TETRAS performance scores.
Key Points
- Wrist neuromodulation reduced clinician-rated tremor scores in most participants
- Patient-selected stimulation waveform produced greater daily-activity improvement
- Prescription device carries Medicare and Veterans Affairs coverage pathways
Longevity Analysis
Tremor erodes independence long before it shortens life, and non-pharmacological control of motor symptoms preserves the fine-motor capacity that underpins eating, writing, and self-care in later decades. The design principle here is notable beyond neurology: stimulation calibrated to the individual's own response outperformed a fixed protocol, reinforcing that peripheral nerve signaling is highly variable between people and that therapy matched to measured response beats standardized dosing. Sustained benefit depends on consistent daily use, which makes coverage and prescription access as decisive as the underlying mechanism.
Original published by Longevity.Technology.